Assembly Biosciences (NASDAQ: ASMB) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are updating our model post the 1Q21 print (no major changes, PT still $13). The stock hit a new all-time low last night, closing at $3.90, and is now trading ~$1.50 below cash value, with enough cash ‘into 2023.’ . . . Here’s the thing: when I look at the HBV landscape, I find it difficult to exclude core inhibitors from what may be the eventual cocktail for finite treatment. Mechanistically, they effectively work upstream of nucs and they knock down HBV RNA better than siRNAs. And when I look at core inhibitors, ASMB has best-in-class potential given it is building its pipeline using novel chemotypes (i.e. should be safer than derivative chemotypes from everything we have seen), and that is even intra-pipeline among its core inhibitors.”
To request access to the full report, visit http://nnw.fm/l4Rxd
About Assembly Biosciences Inc.
Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. For more information, visit the company’s website at www.AssemblyBio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork
